9.80
0.07 (0.72%)
| Penutupan Terdahulu | 9.73 |
| Buka | 9.68 |
| Jumlah Dagangan | 4,077,528 |
| Purata Dagangan (3B) | 2,589,818 |
| Modal Pasaran | 2,928,299,008 |
| Harga / Pendapatan (P/E Ke hadapan) | 59.17 |
| Harga / Jualan (P/S) | 5.65 |
| Harga / Buku (P/B) | 15.39 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Feb 2025 - 3 Mar 2025 |
| Margin Keuntungan | -21.21% |
| Margin Operasi (TTM) | 17.53% |
| EPS Cair (TTM) | -0.340 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 36.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 248.66% |
| Nisbah Semasa (MRQ) | 3.15 |
| Aliran Tunai Operasi (OCF TTM) | -26.52 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.72 M |
| Pulangan Atas Aset (ROA TTM) | 1.16% |
| Pulangan Atas Ekuiti (ROE TTM) | -67.09% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Amicus Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | 0.13 |
|
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.76% |
| % Dimiliki oleh Institusi | 104.43% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 21.00 (Cantor Fitzgerald, 114.29%) | Beli |
| Median | 15.00 (53.06%) | |
| Rendah | 12.00 (Morgan Stanley, 22.45%) | Pegang |
| Purata | 16.00 (63.27%) | |
| Jumlah | 4 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 10.76 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 13 Dec 2024 | 12.00 (22.45%) | Pegang | 9.36 |
| JP Morgan | 12 Nov 2024 | 17.00 (73.47%) | Beli | 10.49 |
| Cantor Fitzgerald | 07 Nov 2024 | 21.00 (114.29%) | Beli | 10.98 |
| Guggenheim | 07 Nov 2024 | 15.00 (53.06%) | Beli | 10.98 |
| B of A Securities | 17 Oct 2024 | 15.00 (53.06%) | Beli | 11.97 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Jan 2025 | Pengumuman | Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook |
| 02 Jan 2025 | Pengumuman | Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
| 06 Nov 2024 | Pengumuman | Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates |
| 01 Nov 2024 | Pengumuman | Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024 |
| 28 Oct 2024 | Pengumuman | Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024 |
| 17 Oct 2024 | Pengumuman | Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |